DE19801646A1 - Substituierte alpha,beta-annellierte Butyrolactone - Google Patents

Substituierte alpha,beta-annellierte Butyrolactone

Info

Publication number
DE19801646A1
DE19801646A1 DE19801646A DE19801646A DE19801646A1 DE 19801646 A1 DE19801646 A1 DE 19801646A1 DE 19801646 A DE19801646 A DE 19801646A DE 19801646 A DE19801646 A DE 19801646A DE 19801646 A1 DE19801646 A1 DE 19801646A1
Authority
DE
Germany
Prior art keywords
alkyl
phenyl
substituted
different
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19801646A
Other languages
German (de)
English (en)
Inventor
Andreas Dr Stolle
Horst-Peter Dr Antonicek
Stephan Dr Lensky
Arnd Dr Voerste
Thomas Dr Mueller
Joerg Dr Baumgarten
Karsten Von Dem Dr Bruch
Gerhard Dr Mueller
Udo Dr Stropp
Ervin Dr Harvath
Jean De Dr Vry
Rudy Dr Schreiber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Priority to DE19801646A priority Critical patent/DE19801646A1/de
Priority to US09/600,355 priority patent/US6462074B1/en
Priority to AU25172/99A priority patent/AU2517299A/en
Priority to DE59902921T priority patent/DE59902921D1/de
Priority to JP2000540132A priority patent/JP2002509144A/ja
Priority to PCT/EP1999/000132 priority patent/WO1999036416A1/de
Priority to ES99904767T priority patent/ES2185316T3/es
Priority to EP99904767A priority patent/EP1047684B1/de
Publication of DE19801646A1 publication Critical patent/DE19801646A1/de
Priority to US10/206,166 priority patent/US6723718B2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
DE19801646A 1998-01-17 1998-01-17 Substituierte alpha,beta-annellierte Butyrolactone Withdrawn DE19801646A1 (de)

Priority Applications (9)

Application Number Priority Date Filing Date Title
DE19801646A DE19801646A1 (de) 1998-01-17 1998-01-17 Substituierte alpha,beta-annellierte Butyrolactone
US09/600,355 US6462074B1 (en) 1998-01-17 1999-01-12 Substituted α, β-anellated butyrolactones
AU25172/99A AU2517299A (en) 1998-01-17 1999-01-12 Substituted alpha,beta-anellated butyrolactones
DE59902921T DE59902921D1 (en) 1998-01-17 1999-01-12 Substituierte alpha,beta-anellierte butyrolactone
JP2000540132A JP2002509144A (ja) 1998-01-17 1999-01-12 置換α，β−縮合ブチロラクトン
PCT/EP1999/000132 WO1999036416A1 (de) 1998-01-17 1999-01-12 SUBSTITUIERTE α,β-ANELLIERTE BUTYROLACTONE
ES99904767T ES2185316T3 (es) 1998-01-17 1999-01-12 Butirolactonas alfa, beta-condensadas sustituidas.
EP99904767A EP1047684B1 (de) 1998-01-17 1999-01-12 Substituierte alpha,beta-anellierte butyrolactone
US10/206,166 US6723718B2 (en) 1998-01-17 2002-07-25 Substituted α, β-anellated butyrolactones

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19801646A DE19801646A1 (de) 1998-01-17 1998-01-17 Substituierte alpha,beta-annellierte Butyrolactone

Publications (1)

Publication Number Publication Date
DE19801646A1 true DE19801646A1 (de) 1999-07-22

Family

ID=7854912

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19801646A Withdrawn DE19801646A1 (de) 1998-01-17 1998-01-17 Substituierte alpha,beta-annellierte Butyrolactone
DE59902921T Expired - Fee Related DE59902921D1 (en) 1998-01-17 1999-01-12 Substituierte alpha,beta-anellierte butyrolactone

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE59902921T Expired - Fee Related DE59902921D1 (en) 1998-01-17 1999-01-12 Substituierte alpha,beta-anellierte butyrolactone

Country Status (7)

Country Link
US (2) US6462074B1 (enExample)
EP (1) EP1047684B1 (enExample)
JP (1) JP2002509144A (enExample)
AU (1) AU2517299A (enExample)
DE (2) DE19801646A1 (enExample)
ES (1) ES2185316T3 (enExample)
WO (1) WO1999036416A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021236449A1 (en) * 2020-05-18 2021-11-25 Gen1E Lifesciences Inc. P38alpha mitogen-activated protein kinase inhibitors
US11357781B2 (en) 2016-06-23 2022-06-14 University Of Maryland, Baltimore Non-catalytic substrate-selective, p38α-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof
US11390581B2 (en) 2020-10-29 2022-07-19 Gen1E Lifesciences Inc. Crystalline 5-(dimethylamino)-n-(4-(morpholinomethyl)phenyl)naphthalene-1-sulfonamide di-hydrochloride di-hydrate
US11555020B2 (en) 2021-03-23 2023-01-17 Gen1E Lifesciences Inc. Substituted naphthyl p38α mitogen-activated protein kinase inhibitors
US11718595B2 (en) 2018-12-07 2023-08-08 University Of Maryland, Baltimore Non-ATP/catalytic site p38 Mitogen Activated Protein Kinase inhibitors

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19932621A1 (de) * 1999-07-13 2001-04-26 Bayer Ag Neue substituerte alpha, beta-anellierte Butyrolactone
WO2005037286A1 (en) 2003-03-25 2005-04-28 Vasopharm Biotech Gmbh Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia
US7311701B2 (en) * 2003-06-10 2007-12-25 Cierra, Inc. Methods and apparatus for non-invasively treating atrial fibrillation using high intensity focused ultrasound
MX2007005113A (es) * 2004-11-03 2007-06-26 Hoffmann La Roche Nuevos derivados de dicarboxamida.
GB0713686D0 (en) 2007-07-13 2007-08-22 Addex Pharmaceuticals Sa New compounds 2
AR078171A1 (es) * 2009-09-15 2011-10-19 Sanofi Aventis Dihidrobenzocicloalquiloximetil-oxazolopirimidinonas sustituidas, preparacion y uso de las mismas

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2605630B1 (fr) * 1986-10-22 1989-06-30 Roussel Uclaf Procede de preparation de derives de l'octahydroindole et intermediaires de preparation
NZ240921A (en) 1990-12-12 1994-06-27 Zymogenetics Inc G protein coupled glutamate receptor (neurotransmitters), recombinant production
GB9324872D0 (en) 1993-12-03 1994-01-19 Univ Pasteur Pharmaceutical compounds
FR2713064B1 (fr) 1993-12-03 1996-01-12 Fantino Gilles Siège dont le dossier articulé fait office de couverture de protection pour l'assise lorsqu'il est rabattu.
US5576323A (en) 1993-12-03 1996-11-19 Eli Lilly And Company Excitatory amino acid receptor antagonists
GB9325368D0 (en) 1993-12-10 1994-02-16 Univ Bristol Organic compounds
GB9325360D0 (en) 1993-12-10 1994-02-16 Univ Bristol Organic compounds
EP0750621B1 (en) 1994-03-14 1999-07-21 Novo Nordisk A/S Heterocyclic compounds, their preparation and use
AU3414295A (en) 1994-08-19 1996-03-14 Nps Pharmaceuticals, Inc. Methods and compounds active at metabotropic glutamate receptors useful for treatment of neurological disorders and diseases
CA2199508A1 (en) * 1994-09-08 1996-03-14 Darryle Darwin Schoepp Excitatory amino acid receptor antagonists
US5717109A (en) 1994-09-08 1998-02-10 Eli Lilly And Company Excitatory amino acid receptor antagonists
JP3993651B2 (ja) 1994-10-21 2007-10-17 アスビオファーマ株式会社 シクロプロパクロメンカルボン酸誘導体
WO1996015099A1 (en) * 1994-11-09 1996-05-23 Novo Nordisk A/S Heterocyclic compounds, their preparation and use
US5701168A (en) 1995-06-29 1997-12-23 Bell Communications Research, Inc. Inverse twisted and super-twisted nematic liquid crystal device
EP0843660A1 (en) 1995-07-31 1998-05-27 Novo Nordisk A/S Heterocyclic compounds, their preparation and use
US5945417A (en) 1995-07-31 1999-08-31 Novo Nordisk Heterocyclic compounds, their preparation and use
US5688826A (en) 1995-11-16 1997-11-18 Eli Lilly And Company Excitatory amino acid derivatives
CA2237910C (en) * 1995-11-16 2005-12-27 Eli Lilly And Company Excitatory amino acid derivatives
GB9605429D0 (en) 1995-11-16 1996-05-15 Lilly Co Eli Excitatory amino acid receptor antagonists

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11357781B2 (en) 2016-06-23 2022-06-14 University Of Maryland, Baltimore Non-catalytic substrate-selective, p38α-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof
US11911393B2 (en) 2016-06-23 2024-02-27 University Of Maryland, Baltimore Non-catalytic substrate-selective p38alpha-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof
US11911392B2 (en) 2016-06-23 2024-02-27 University Of Maryland, Baltimore Non-catalytic substrate-selective p38α-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof
US11718595B2 (en) 2018-12-07 2023-08-08 University Of Maryland, Baltimore Non-ATP/catalytic site p38 Mitogen Activated Protein Kinase inhibitors
US12202810B2 (en) 2018-12-07 2025-01-21 University Of Maryland, Baltimore Non-ATP/catalytic site p38 mitogen activated protein kinase inhibitors
CN116406355A (zh) * 2020-05-18 2023-07-07 Gen1E生命科学公司 P38α促分裂原活化蛋白激酶抑制剂
WO2021236449A1 (en) * 2020-05-18 2021-11-25 Gen1E Lifesciences Inc. P38alpha mitogen-activated protein kinase inhibitors
US11440918B2 (en) 2020-05-18 2022-09-13 Gen1E Lifesciences Inc. p38α mitogen-activated protein kinase inhibitors
US11926635B2 (en) 2020-05-18 2024-03-12 Gen1E Lifesciences Inc. P38α mitogen-activated protein kinase inhibitors
US11286260B2 (en) 2020-05-18 2022-03-29 Gen1E Lifesciences Inc. P38α mitogen-activated protein kinase inhibitors
US11390581B2 (en) 2020-10-29 2022-07-19 Gen1E Lifesciences Inc. Crystalline 5-(dimethylamino)-n-(4-(morpholinomethyl)phenyl)naphthalene-1-sulfonamide di-hydrochloride di-hydrate
US12269792B2 (en) 2020-10-29 2025-04-08 Genie Lifesciences Inc. Crystalline 5-(dimethylamino)-N-(4-(morpholinomethyl) phenyl)naphthalene-1-sulfonamide di-hydrochloride di-hydrate
US11555020B2 (en) 2021-03-23 2023-01-17 Gen1E Lifesciences Inc. Substituted naphthyl p38α mitogen-activated protein kinase inhibitors
US11976049B2 (en) 2021-03-23 2024-05-07 Gen1E Lifesciences Inc. Substituted naphthyl p38alpha mitogen-activated protein kinase inhibitors
US12331024B2 (en) 2021-03-23 2025-06-17 Gen1E Lifesciences Inc. Substituted naphthyl P38alpha mitogen-activated protein kinase inhibitors

Also Published As

Publication number Publication date
US6462074B1 (en) 2002-10-08
DE59902921D1 (en) 2002-11-07
EP1047684A1 (de) 2000-11-02
WO1999036416A1 (de) 1999-07-22
AU2517299A (en) 1999-08-02
ES2185316T3 (es) 2003-04-16
US20030158424A1 (en) 2003-08-21
EP1047684B1 (de) 2002-10-02
JP2002509144A (ja) 2002-03-26
US6723718B2 (en) 2004-04-20

Similar Documents

Publication Publication Date Title
EP0546388A1 (de) Azaheterocyclylmethyl-chromane als Wirkstoffe zur Behandlung von Erkrankungen des Zentralnervensystems
EP1181294B1 (de) Neue derivate und analoga von galanthamin
DE19801646A1 (de) Substituierte alpha,beta-annellierte Butyrolactone
EP0571870B1 (de) Cyclopentan- und -penten-beta-Aminosäuren
WO1996005837A1 (de) Verwendung von n-substituierten phenothiazinen
EP0749970B1 (de) Benzisothiazolyl-substituierte Aminomethylchromane
WO2001047899A1 (de) Substituierte piperazinderivateals inhibitoren des mtp
EP0546389B1 (de) Piperidylmethyl substituierte Chromanderivate als Wirkstoffe zur Behandlung von Erkrankungen des Zentralnervensystems
DE3630903A1 (de) Neue tetrahydronaphthalin- und indanderivate, verfahren zu deren herstellung sowie diese enthaltende arzneimittel
EP0519291B1 (de) Aminomethyl-substituierte 2,3-Dihydropyrano(2,3-b)pyridine, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln
EP0539803B1 (de) Triazaspirodecanon-Methyl-Chromane zur Bekämpfung von Erkrankungen des Zentralnervensystems
DE19801636A1 (de) Substituierte bicyclische Lactone
EP1157020B1 (de) Substituierte 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DD279238A5 (de) Verfahren zur herstellung von benzocycloheptenderivaten
DE19509697A1 (de) Neue Borneole, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
DE19932621A1 (de) Neue substituerte alpha, beta-anellierte Butyrolactone
DE19801647A1 (de) Substituierte beta,gamma-annellierte Lactone
DE19904397A1 (de) Verwendung von Pyrazol-Carbonsäureamiden
EP0698597B1 (de) Cyclohexadienderivate
EP0538691A1 (de) Substituierte Tetrahydrothiophene, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE19801648A1 (de) alpha-Substituierte Lactone
DE19904396A1 (de) Substituierte Pyrazolbenzylamin-Derivate
EP0538689A1 (de) Neue substituierte 2,3-Dihydropyrane, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee